Navigation path

Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

Vincaleukoblastin-23-oic acid, O4-deacetyl-2-[(2-mercaptoethoxy)carbonyl]hydrazide, disulfide with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-gamma-glutamyl-L-alpha-aspartyl-L-arginyl-L-alpha-aspartyl-L-alpha-aspartyl-L-cysteine

EU orphan designation number: EU/3/12/959
Active ingredient: Vincaleukoblastin-23-oic acid, O4-deacetyl-2-[(2-mercaptoethoxy)carbonyl]hydrazide, disulfide with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-gamma-glutamyl-L-alpha-aspartyl-L-arginyl-L-alpha-aspartyl-L-alpha-aspartyl-L-cysteine
Indication: Treatment of ovarian cancer
Sponsor: Endocyte Europe B.V.
Prins Bernhardplein 200, 1097 JB Amsterdam, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/02/2012 Orphan designation EMA/OD/094/11 (2012)885 of 09/02/2012
12/08/2016 Removal of orphan designation from Community Register